| EGFR positive n = 100 | EGFR negative n = 32 | p value |
---|---|---|---|
EGFR mutation with PCR clamp, n (%) | Â | Â | 0.012 |
 19del | 55 (55) | 10 (31) |  |
 L858R | 36 (36) | 21 (66) |  |
 L861Q | 4 (4) | 0 (0) |  |
 G719X | 5 (5) | 1 (3) |  |
 T790 M | 1 (1)a | 0 (0) |  |
Tumour histological type, n (%) | Â | Â | 0.52 |
 Adenocarcinoma | 96 (96) | 32 (100) |  |
 Squamous cell carcinoma | 3 (3) | 0 (0) |  |
 NSCLC with morphological squamous cell and adenocarcinoma patterns | 1 (1) | 0 (0) |  |
TKI therapy, n (%) | 87 (87) | 23 (72) | 0.29 |
Gefitiniba | 52 (60) | 12 (52) | Â |
Erlotiniba | 16 (18) | 7 (30) | Â |
Afatiniba | 18 (21) | 4 (17) | Â |
Naquotiniba | 1 (1) | 0 (0) | Â |
Number of chemotherapies before TKI therapy, n (%)a | Â | Â | .08 |
 0 regimen | 56 (64) | 9 (39) |  |
 1 regimen | 27 (31) | 10 (43) |  |
 2 regimens | 3 (3) | 3 (13) |  |
 3 regimens | 1 (1) | 1 (4) |  |
Response to TKI, n (%)b | Â | Â | 0.59 |
 PR/CR | 64 (74) | 15 (65) |  |
 SD | 8 (9) | 4 (17) |  |
 PD | 8 (9) | 3 (13) |  |
 NA | 7 (8) | 1 (4) |  |
PFS for the first TKI therapy, m, median (95%CI) | 12.2 (9.3–16) | 12.4 (7.3–13.3) | 0.24 |
Tumour content ratioc, %, median (IQR) | 19 (11–32) | 11 (5–18) | 0.002 |